Recombinant PreS‐fusion protein vaccine for birch pollen and apple allergy
Authors:
- Musa KhaitovMKMusa Khaitov
- Igor ShilovskiyISIgor Shilovskiy
- Rudolf ValentaRVRudolf Valenta
- Milena WeberMWMilena Weber
- Artem KorneevAKArtem Korneev
- Inna TulaevaITInna Tulaeva
- Pia GattingerPGPia Gattinger
- Marianne van HageMHMarianne van Hage
- Gerhard HoferGHGerhard Hofer
- Jon R. KonradsenJKJon R. Konradsen
- Walter KellerWKWalter Keller
- Oluwatoyin AkinfenwaOAOluwatoyin Akinfenwa
Abstract
Background: IgE cross‐sensitization to major birch pollen allergen Bet v 1 and pathogenesis‐related (PR10) plant food allergens is responsible for the pollen‐food allergy syndrome.Methods: We designed a recombinant protein, AB‐PreS, consisting of non‐allergenic peptides derived from the IgE‐binding sites of Bet v 1 and the cross‐reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB‐PreS was expressed in E. coli and purified by chromatography. The allergenic and inflammatory activity of AB‐PreS was tested using basophils and PBMCs from birch pollen allergic patients. The ability of antibodies induced by immunization of rabbits with AB‐PreS and birch pollen extract‐based vaccines to inhibit allergic patients IgE binding to Bet v 1 and Mal d 1 was assessed by ELISA.Results: IgE‐binding experiments and basophil activation test revealed the hypoallergenic nature of AB‐PreS. AB‐PreS induced lower T‐cell activation and inflammatory cytokine production in cultured PBMCs from allergic patients. IgG antibodies induced by five injections with AB‐PreS inhibited allergic patients' IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract‐based vaccines. Additionally, immunization with AB‐PreS induced HBV‐specific antibodies potentially protecting from infection with HBV.Conclusion: The recombinant AB‐PreS‐based vaccine is hypoallergenic and superior over currently registered allergen extract‐based vaccines regarding the induction of blocking antibodies to Bet v 1 and Mal d 1 in animals.Keywords
All Related Versions
Funding Information
- Austrian Science Fund
- Megagrants
This publication has 67 references indexed in Scilit:
- Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical ImmunologyAllergy, 2013
- Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapyJournal of Allergy and Clinical Immunology, 2013
- A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreS–Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 PhenotypeThe Journal of Immunology, 2013
- Mapping of Conformational IgE Epitopes with Peptide-Specific Monoclonal Antibodies Reveals Simultaneous Binding of Different IgE Antibodies to a Surface Patch on the Major Birch Pollen Allergen, Bet v 1The Journal of Immunology, 2011
- Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivativesClinical & Experimental Allergy, 2008
- Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1–related food allergensJournal of Allergy and Clinical Immunology, 2005
- Pre-S1 Antigen-Dependent Infection of Tupaia Hepatocyte Cultures with Human Hepatitis B VirusJournal of Virology, 2003
- Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergyJournal of Allergy and Clinical Immunology, 2000
- X-ray and NMR structure of Bet v 1, the origin of birch pollen allergyNature Structural & Molecular Biology, 1996
- Immunotherapy with partially purified and standardized tree pollen extractsAllergy, 1988